Courtney D DiNardo, MD, MSCE

DiNardo CD et al. Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia. J Clin Oncol 2021;JCO2003736. Abstract

Lachowiez C et al. A phase IB/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies. EHA 2021;Abstract S136.

Pratz KW et al. Measurable residual disease response in acute myeloid leukemia treated with venetoclax and azacitidine. ASCO 2021;Abstract 7018.

Yilmaz M et al. Triple combination of HMA, venetoclax, and FLT3 inhibitor produces higher FLT3 PCR clearance, flow MRD negativity, and improved median OS compared with doublets of HMA with FLT3 inhibitor. EHA 2021;Abstract EP464.

Gail J Roboz, MD

Fenaux P et al. Luspatercept in patients with lower-risk myelodysplastic syndromes. N Engl J Med 2020;382(2):140-51. Abstract

Garcia-Manero G et al. Oral cedazuridine/decitabine for MDS and CMML: A phase 2 pharmacokinetic/pharmacodynamic randomized crossover study. Blood 2020;136(6):674-83. Abstract

Platzbecker U et al. Imerge: A phase 3 study to evaluate imetelstat in transfusion-dependent subjects with IPSS low or intermediate-1 risk myelodysplastic syndromes (MDS) that is relapsed/refractory to erythropoiesis-stimulating agent (ESA) treatment. ASH 2020;Abstract 3113.

Sallman D et al. The first-in-class anti-CD47 antibody magrolimab combined with azacitidine is well-tolerated and effective in MDS patients: Phase 1b results. EHA 2020;Abstract S187.

Zeidan AM et al. A phase 1b study evaluating the safety and efficacy of venetoclax in combination with azacitidine for the treatment of relapsed/refractory myelodysplastic syndrome. ASH 2020;Abstract 3109.

Eytan M Stein, MD

DiNardo CD et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia.  N Engl J Med 2020;383(7):617-29 Abstract

Lancet JE et al. Five-year final results of a phase III study of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML. J Clin Oncol 2020;38(15):7510. Abstract

Pullarkat V et al. Preliminary results of V-FAST, a phase 1b master trial to investigate CPX-351 combined with targeted agents in newly diagnosed AML. ASCO 2021;Abstract 7026.

Pullarkat V et al. Venetoclax and azacitidine combination in chemotherapy ineligible untreated patients with therapy-related myeloid neoplasms, antecedent myelodysplastic syndromes, or myelodysplastic/myeloproliferative neoplasms. ASCO 2021;Abstract 7011.